Ptpn11 Is A Novel Anti-Fibrotic Gene In Idiopathic Pulmonary Fibrosis

被引：0
作者：
Tzouvelekis, A. [1 ,2 ]
Cardenas, C. Lacks Lino [2 ]
Yu, G. [1 ]
Sakamoto, K. [1 ]
DeIuliis, J. [1 ]
Wyllie, A. [3 ]
Ahangari, F. [1 ]
Woolard, T. [1 ]
Heather, L. [1 ]
Herazo-Maya, J. D. [1 ]
Kaminski, N. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Yale Univ, New Haven, CT USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2356
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Hyperthrophic cardiomyopathy and the PTPN11 gene
    Sarkozy, A
    Conti, E
    Lepri, FR
    Pizzuti, A
    Dallapiccola, B
    Autore, C
    Tartaglia, M
    Tartaglia, M
    Lepri, FR
    Pizzuti, A
    Dallapiccola, B
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2005, 136A (01) : 93 - 94
  • [42] A novel PTPN11 gene mutation in a patient with LEOPARD syndrome
    Du-Thanh, Aurelie
    Cave, Helene
    Bessis, Didier
    Puso, Carine
    Guilhou, Jean-Jacques
    Dereure, Olivier
    ARCHIVES OF DERMATOLOGY, 2007, 143 (09) : 1210 - 1211
  • [43] Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
    Sara De Biasi
    Stefania Cerri
    Elena Bianchini
    Lara Gibellini
    Elisa Persiani
    Gloria Montanari
    Fabrizio Luppi
    Cristiano Matteo Carbonelli
    Luigi Zucchi
    Marialuisa Bocchino
    Alessandro Sanduzzi Zamparelli
    Carlo Vancheri
    Giacomo Sgalla
    Luca Richeldi
    Andrea Cossarizza
    BMC Medicine, 13
  • [44] WEIGHT LOSS HAS A SIGNIFICANT IMPACT ON ANTI-FIBROTIC DRUG TOLERANCE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Moon, R. D. C.
    Barker, E.
    Agnew, S.
    Sutcliffe, J.
    Kwok, A.
    Spencer, L. G.
    THORAX, 2017, 72 : A250 - A250
  • [45] Anti-Fibrotic Role Of Inhaled Interferon-γ Detected By Proteomic Studies In Patients With Idiopathic Pulmonary Fibrosis
    Hasaneen, N. A.
    Haley, J.
    Foda, H. D.
    Condos, R.
    Smaldone, G. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [46] Correction to: Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis
    Takumi Yoshikawa
    Mitsuo Otsuka
    Hirofumi Chiba
    Kimiyuki Ikeda
    Yuki Mori
    Yasuaki Umeda
    Hirotaka Nishikiori
    Koji Kuronuma
    Hiroki Takahashi
    BMC Pulmonary Medicine, 20
  • [47] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [48] Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy
    Pascoe, Amy
    Smallwood, Natasha
    RESPIROLOGY, 2023, 28 (11) : 978 - 979
  • [49] Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments
    De Biasi, Sara
    Cerri, Stefania
    Bianchini, Elena
    Gibellini, Lara
    Persiani, Elisa
    Montanari, Gloria
    Luppi, Fabrizio
    Carbonelli, Cristiano Matteo
    Zucchi, Luigi
    Bocchino, Marialuisa
    Zamparelli, Alessandro Sanduzzi
    Vancheri, Carlo
    Sgalla, Giacomo
    Richeldi, Luca
    Cossarizza, Andrea
    BMC MEDICINE, 2015, 13
  • [50] ELIGIBILITY FOR ANTI-FIBROTIC TREATMENT IN IDIOPATHIC PULMONARY FIBROSIS (IPF) DEPENDS ON THE PREDICTIVE EQUATION USED IN PULMONARY FUNCTION TESTING
    Burgess, Andrew
    Goon, Ken
    Attia, John
    Palazzi, Kerrin
    Brannan, John
    Grainge, Christopher
    RESPIROLOGY, 2017, 22 : 46 - 46
12345